Vagistat-1

Onychomycosis, Inflammation, Cellulitis + 5 more
Treatment
20 Active Studies for Vagistat-1

What is Vagistat-1

TioconazoleThe Generic name of this drug
Treatment SummaryTioconazole is a medication used to treat fungal and yeast infections. It comes in topical formulations which can be used to treat common skin infections like ringworm, jock itch, athlete's foot, and sun fungus. Tioconazole works by blocking the production of an important component of the yeast cell membrane, leading to increased permeability and ultimately killing the fungus.
Vagistat-1is the brand name
Vagistat-1 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Vagistat-1
Tioconazole
1997
32

Effectiveness

How Vagistat-1 Affects PatientsTioconazole is a medication used to fight fungal yeast infections. It kills or stops the growth of fungi like Candida albicans and Torulopsis glabrata. Tioconazole works by blocking the production of substances needed to keep fungi cells alive. It won't work for illnesses caused by bacteria or viruses.
How Vagistat-1 works in the bodyTioconazole works by stopping a specific enzyme from making the molecule ergosterol, which is needed in the cell membrane of yeast. When this molecule isn't present, the yeast cell becomes more permeable. Tioconazole can also have other effects on the yeast, such as inhibiting respiration, blocking the movement of calcium and potassium ions, and preventing the yeast from changing into its fungal form.

When to interrupt dosage

The endorsed dose of Vagistat-1 is contingent upon the acknowledged condition, including Vulvovaginal Candidiasis, cutaneous dermatophyte infection and Infection, Mixed. The quantity of dosage deviates, in accordance with the administration technique (e.g. Ointment - Vaginal or Topical) featured in the table beneath.
Condition
Dosage
Administration
Onychomycosis
300.0 mg, , 0.065 mg/mg, 0.3 mg/mg, 6.5 %, 1.0 %, 7.5 %, 0.01 mg/mg
Vaginal, Ointment - Vaginal, Ointment, , Topical, Ointment - Topical, Cream, Cream - Topical, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Cream; Ointment - Topical; Vaginal, Cream; Ointment, Topical; Vaginal, Suppository, Suppository - Vaginal
Coinfection
300.0 mg, , 0.065 mg/mg, 0.3 mg/mg, 6.5 %, 1.0 %, 7.5 %, 0.01 mg/mg
Vaginal, Ointment - Vaginal, Ointment, , Topical, Ointment - Topical, Cream, Cream - Topical, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Cream; Ointment - Topical; Vaginal, Cream; Ointment, Topical; Vaginal, Suppository, Suppository - Vaginal
Cellulitis
300.0 mg, , 0.065 mg/mg, 0.3 mg/mg, 6.5 %, 1.0 %, 7.5 %, 0.01 mg/mg
Vaginal, Ointment - Vaginal, Ointment, , Topical, Ointment - Topical, Cream, Cream - Topical, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Cream; Ointment - Topical; Vaginal, Cream; Ointment, Topical; Vaginal, Suppository, Suppository - Vaginal
Candidiasis, Vulvovaginal
300.0 mg, , 0.065 mg/mg, 0.3 mg/mg, 6.5 %, 1.0 %, 7.5 %, 0.01 mg/mg
Vaginal, Ointment - Vaginal, Ointment, , Topical, Ointment - Topical, Cream, Cream - Topical, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Cream; Ointment - Topical; Vaginal, Cream; Ointment, Topical; Vaginal, Suppository, Suppository - Vaginal
Tinea Pedis
300.0 mg, , 0.065 mg/mg, 0.3 mg/mg, 6.5 %, 1.0 %, 7.5 %, 0.01 mg/mg
Vaginal, Ointment - Vaginal, Ointment, , Topical, Ointment - Topical, Cream, Cream - Topical, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Cream; Ointment - Topical; Vaginal, Cream; Ointment, Topical; Vaginal, Suppository, Suppository - Vaginal
cutaneous dermatophyte infection
300.0 mg, , 0.065 mg/mg, 0.3 mg/mg, 6.5 %, 1.0 %, 7.5 %, 0.01 mg/mg
Vaginal, Ointment - Vaginal, Ointment, , Topical, Ointment - Topical, Cream, Cream - Topical, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Cream; Ointment - Topical; Vaginal, Cream; Ointment, Topical; Vaginal, Suppository, Suppository - Vaginal
Candidiasis, Vulvovaginal
300.0 mg, , 0.065 mg/mg, 0.3 mg/mg, 6.5 %, 1.0 %, 7.5 %, 0.01 mg/mg
Vaginal, Ointment - Vaginal, Ointment, , Topical, Ointment - Topical, Cream, Cream - Topical, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Cream; Ointment - Topical; Vaginal, Cream; Ointment, Topical; Vaginal, Suppository, Suppository - Vaginal
Inflammation
300.0 mg, , 0.065 mg/mg, 0.3 mg/mg, 6.5 %, 1.0 %, 7.5 %, 0.01 mg/mg
Vaginal, Ointment - Vaginal, Ointment, , Topical, Ointment - Topical, Cream, Cream - Topical, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Cream; Ointment - Topical; Vaginal, Cream; Ointment, Topical; Vaginal, Suppository, Suppository - Vaginal

Warnings

There are 20 known major drug interactions with Vagistat-1.
Common Vagistat-1 Drug Interactions
Drug Name
Risk Level
Description
Cariprazine
Major
The metabolism of Cariprazine can be decreased when combined with Tioconazole.
Eliglustat
Major
The metabolism of Eliglustat can be decreased when combined with Tioconazole.
Entrectinib
Major
The metabolism of Entrectinib can be decreased when combined with Tioconazole.
Fentanyl
Major
The metabolism of Fentanyl can be decreased when combined with Tioconazole.
Infigratinib
Major
The metabolism of Infigratinib can be decreased when combined with Tioconazole.
Vagistat-1 Toxicity & Overdose RiskOverdosing on the drug can cause redness, stinging, blistering, swelling, itching, hives, burning, and general skin irritation, as well as cramps.
image of a doctor in a lab doing drug, clinical research

Vagistat-1 Novel Uses: Which Conditions Have a Clinical Trial Featuring Vagistat-1?

191 separate studies are currently being conducted to explore Vagistat-1's potential to mitigate cutaneous dermatophyte infection, superficial Fungal skin infection and Communicable Diseases.
Condition
Clinical Trials
Trial Phases
Candidiasis, Vulvovaginal
2 Actively Recruiting
Not Applicable, Phase 3
Inflammation
57 Actively Recruiting
Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4
cutaneous dermatophyte infection
0 Actively Recruiting
Cellulitis
0 Actively Recruiting
Tinea Pedis
0 Actively Recruiting
Onychomycosis
0 Actively Recruiting
Coinfection
0 Actively Recruiting
Candidiasis, Vulvovaginal
0 Actively Recruiting

Vagistat-1 Reviews: What are patients saying about Vagistat-1?

5Patient Review
4/28/2014
Vagistat-1 for Yeast Infection of Vagina and Vulva
This was much more effective than Monistat, and the itching wasn't nearly as bad.
5Patient Review
2/7/2022
Vagistat-1 for Yeast Infection of Vagina and Vulva
This treatment completely knocked out all of my symptoms overnight! I woke up feeling normal again. Some people might be more sensitive to this product, but it worked great for me even though I'm usually quite sensitive.
4.3Patient Review
4/13/2022
Vagistat-1 for Yeast Infection of Vagina and Vulva
I'm only a couple hours into using this, but so far it's been much better than Monistat in terms of burning and itching.
3.3Patient Review
9/3/2022
Vagistat-1 for Yeast Infection of Vagina and Vulva
I'm trying this brand for the first time and chose the Vagistat 1 because I wanted to avoid leakage for more than a week. After insertion, I felt burning which is something I expected. It's not too bad though. So far, so good. I'll update my review once I know more about what's going on.
2.7Patient Review
4/25/2022
Vagistat-1 for Yeast Infection of Vagina and Vulva
The burning and pain was unbearable. My vulva was so swollen, it hurt to walk. I have chronic infections, so I'm used to calling and getting fluconazole. Since it was a Sunday, I decided to try this treatment instead. Big mistake.
2.3Patient Review
12/5/2019
Vagistat-1 for Yeast Infection of Vagina and Vulva
My condition only deteriorated after using this treatment.
1.7Patient Review
10/14/2014
Vagistat-1 for Yeast Infection of Vagina and Vulva
The burning and swelling is really bad. My yeast infection wasn't that serious to begin with, but now it's ten times worse. Has anyone else experienced this? And if so, what did you do to make the swelling go down? Or has it gone away on its own eventually?
1.7Patient Review
4/7/2014
Vagistat-1 for Yeast Infection of Vagina and Vulva
I found this site helpful, thank you. I used Vagistate 1 a few hours ago and now I'm experiencing burning on my vulva, swelling, and redness. I went to the med clinic and they told me I have a bladder infection and am also having a bad reaction to the Vagistate 1. Let's hope the ice or bath ideas work because this is severe.
1Patient Review
3/24/2013
Vagistat-1 for Yeast Infection of Vagina and Vulva
I'm really surprised this product is still on the market. The burning, itching, and swelling were almost immediate and unbearable. I had to get in the bathtub and wash most of it off. Benadryl also helped with the swelling. I definitely recommend monistat-3 instead.
1Patient Review
10/16/2021
Vagistat-1 for Yeast Infection of Vagina and Vulva
I would not recommend this treatment to anyone. It made my very mild yeast infection much worse. I'm still in pain 12 hours later. Get Monistat 3 day or 7 day instead.
1Patient Review
2/2/2022
Vagistat-1 for Yeast Infection of Vagina and Vulva
I took this medication and saw zero relief. In fact, I'm now in more pain than before, with added burning, itching, and swelling. Do not bother using this product.
1Patient Review
10/2/2022
Vagistat-1 for Yeast Infection of Vagina and Vulva
Do not bother with this medication! I put it on 12 hours ago and the burning, swelling, and pain is unbearable. I've never had such a horrible experience with any yeast infection medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vagistat-1

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How effective is vagistat?

"Vagistat-1 has an average rating of 6.5 from 18 ratings for the treatment of Vaginal Yeast infection. 50% reported a positive experience, while 22% reported a negative experience."

Answered by AI

How long does vagistat-1 take to work?

"If you use the one-day treatment, you should start seeing some improvement in your symptoms within a day. However, it may take up to a week for your symptoms to completely go away."

Answered by AI

Are vagistat and MONISTAT the same?

"Vagisil will help relieve itching, but it does not contain an antifungal to help the source of the infection. There is a product called Vagistat, from the manufacturers of Vagisil, which contains miconazole in an internal and external cream and is similar to Monistat 3."

Answered by AI

Does vagistat cure yeast infection?

"This drug is used to treat vaginal yeast infections. Miconazole decreases vaginal irritation, itching, and discharge that may happen with this condition. This drug is an azole antifungal. It works by preventing the growth of yeast (fungus) that causes the infection."

Answered by AI

Clinical Trials for Vagistat-1

Image of UConn Health in Farmington, United States.

Cognitive Remediation for Memory and Thinking Difficulties

18+
All Sexes
Farmington, CT
The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation ("brain training") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are: * Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction? * Will treatment effects be maintained over time, leading to better long term cognitive outcomes? * Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement? * Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction. Participation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including: * Initial intake visit: Eligibility confirmation (\~2-3 hours) * Computer activities: About 5 hours per week for \~6 weeks (total \~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase * Weekly remote check-in meetings: \~30 minutes each during treatment * Blood draws: Two sessions (before and after treatment), \~20-30 minutes each * Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)
Waitlist Available
Has No Placebo
UConn HealthCutter Lindbergh, Ph.D.
Have you considered Vagistat-1 clinical trials? We made a collection of clinical trials featuring Vagistat-1, we think they might fit your search criteria.Go to Trials
Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies
Phase 2
Recruiting
Abcentra Investigational Site (+6 Sites)Abcentra
Image of School of Public Health in Bloomington, United States.

High Salt Intake for High Blood Pressure

60 - 85
All Sexes
Bloomington, IN
Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury/impaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.
Recruiting
Has No Placebo
School of Public Health
Image of Tesla MedBed at Tampa-FL in Tampa, United States.

Biophoton Therapy for Stem Cell Proliferation

18 - 70
All Sexes
Tampa, FL
Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can increase self-grown stem cells naturally. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in impacting stem cells. Approximately 46 volunteers who want to increase self-grown stem cells will participate in the study. Study Randomization The biostatistician will prepare a randomization schedule including a serial of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. Other than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants, will be blinded about who received which product during the first two weeks of study participation.
Recruiting
Online Trial
Tesla MedBed at Tampa-FL (+1 Sites)James Z Liu, MD, PhD
Have you considered Vagistat-1 clinical trials? We made a collection of clinical trials featuring Vagistat-1, we think they might fit your search criteria.Go to Trials
Image of Goldring Center for High Performance Sport in Toronto, Canada.

Physical Activity for Delayed Onset Muscle Soreness

18 - 35
All Sexes
Toronto, Canada
After completing novel activity or exercise we may experience exercise-induced muscle damage (EIMD), resulting in a period of reduced muscle function and delayed onset muscle soreness (DOMS). DOMS is characterized by muscle pain and tenderness that typically resolves within a week. While the precise cause of DOMS is unknown, there is growing evidence implicating damage to the connective tissue that surrounds our muscle fibers and is related to a small amount of inflammation. This inflammation is a normal part of our body's ability to recovery from injuries and may be visualized through the use of ultrasound technology. A variety of recovery techniques have been proposed that may help with the recovery of DOMS such as massage and electrical muscle stimulation, but these are not always accessible. Therefore, we are interested in investigating whether the number of daily steps can affect how you experience DOMS.
Waitlist Available
Has No Placebo
Goldring Center for High Performance Sport
Image of UCSF in San Francisco, United States.

Moisturizers for Aging

65+
All Sexes
San Francisco, CA
This is a randomized, investigator-blinded, self-controlled pilot study of the physiologic response to topical moisturizers among older adults with dry skin. The overarching hypothesis is that skin barrier decline is an important source of chronic inflammation, and that skin barrier restoration with moisturizers can reduce serum biomarkers of inflammation. The primary objective is to determine the feasibility for a larger trial, and the secondary objectives are to determine the extent to which measures of serum inflammation, skin barrier function, and the skin microbiome change in response to moisturizers. Participants will be asked to apply one of two topical moisturizers that are widely available over the counter in the US (Vaseline® 100% pure petroleum jelly or CeraVe® moisturizing cream) once daily for 4 weeks to the front of the torso, buttocks, arms, and legs. Subjects will act as their own control (i.e. they will be asked to apply the study moisturizer they are randomized to for one intervention period (4 weeks) and not to apply topical moisturizers for the other 4- week intervention period). Participants will be randomized in a 1:1:1:1 ratio to one of 4 treatment groups: i. no intervention then CeraVe; ii. CeraVe then no intervention; iii. no intervention then Vaseline; iv. Vaseline then no intervention. At each visit (baseline, week 4, and week 8), participants will undergo skin barrier testing, skin microbiome sampling, and phlebotomy to measure serum inflammatory markers.
Phase 4
Recruiting
UCSFKatrina Abuabara, MD
Have you considered Vagistat-1 clinical trials? We made a collection of clinical trials featuring Vagistat-1, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security